/
CBDBY
$0.66+$0.01 (+1.93%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.45 – $0.78
65% from low
Borrow rate
7.32%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$0.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.63B | $26.49B | $28.84B | $16.80B | $16.30B | $17.32B | $19.25B | $21.55B |
| Cost of revenue | $33.59B | $19.05B | $21.23B | $11.94B | $11.94B | $13.02B | $14.43B | $16.82B |
| Gross profit | $11.05B | $7.44B | $7.61B | $4.86B | $4.36B | $4.30B | $4.82B | $4.73B |
| Gross margin | 24.8% | 28.1% | 26.4% | 28.9% | 26.7% | 24.8% | 25.0% | 22.0% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $1.57B | $2.78B | $707.2M | $892.0M | $1.74B | −$360.0M | $97.0M | −$33.3M |
| EBITDA | $3.06B | $4.16B | $2.16B | $3.81B | $2.31B | $1.90B | $2.18B | $674.5M |
| Net income | $507.0M | $1.15B | $790.0M | $2.18B | $802.0M | −$172.0M | −$2.27B | −$2.76B |
| Net margin | 1.1% | 4.3% | 2.7% | 13.0% | 4.9% | -1.0% | -11.8% | -12.8% |
| EPS (diluted) | 2.32 | 4.55 | 1.42 | 8.12 | 2.98 | -0.64 | -8.26 | -6.18 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19.8B | $-0.80 | $-0.84–$-0.77 | 1 |
| 2027 | $20.9B | $-0.42 | $-0.44–$-0.40 | 1 |
| 2028 | $20.7B | $-0.22 | $-0.23–$-0.21 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Held by traders on TradeandTell
No one on the platform currently holds CBDBY.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CBDBY as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CBDBY yet.